Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 11;12(8):1936.
doi: 10.3390/diagnostics12081936.

Systematic Review and Meta-Analysis of the Susceptibility of ABO Blood Groups to Venous Thromboembolism in Individuals with Factor V Leiden

Waleed M Bawazir  1   2
Affiliations
Review

Systematic Review and Meta-Analysis of the Susceptibility of ABO Blood Groups to Venous Thromboembolism in Individuals with Factor V Leiden

Waleed M Bawazir. Diagnostics (Basel). .

Abstract

A limited number of studies investigated the association between the ABO blood groups and the incidence of venous thromboembolism in individuals with Factor V Leiden; however, discordant findings were reported. Consequently, this systematic review and meta-analysis aimed to evaluate the existing evidence on the susceptibility of the ABO blood group to venous thromboembolism in individuals with Factor V Leiden. All English-published articles on the Web of Science, Scopus, PubMed, EMBASE, and Google Scholar were comprehensively and systematically searched by the author without a time or region limit. Four studies were included in the qualitative synthesis and meta-analysis after the removal of studies that were not eligible. According to the analyses of the fixed and random effects, the point estimates of the effect size and the 95% confidence interval were 0.416 (95% CI: 0.397−0.435) and 0.392 (95% CI: 0.288−0.507), respectively. In contrast, the homogeneity test (Q value) reveals that blood group data distributions have a heterogenous structure (Q = 432.187; p-value < 0.001). The pooled event rates and the 95% CIs for the A, AB, B, and O-blood groups were 0.518 (95% CI: 0.411−0.622), 0.592 (95% CI: 0.495−0.683), 0.205 (95% CI: 0.041−0.612), and 0.283 (95% CI: 0.247−0.322), respectively. According to the findings, people with Factor V Leiden with blood group AB are more likely to develop venous thromboembolism than those with blood groups A, O, and B. The overall statistical significance of the ABO blood group’s susceptibility to venous thromboembolism in individuals with Factor V Leiden was <0.001 (pooled p-value). In conclusion, the current meta-analysis provides an additional indication that blood group AB individuals with Factor V Leiden are at higher risk of developing venous thromboembolism, and blood type B is connected to a lower risk of developing venous thromboembolism.

Keywords: ABO blood group; factor V Leiden; meta-analysis; susceptibility; systematic review; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

The author declared that there is no conflict of interest in this work.

Figures

Figure 1
Figure 1
The PRISMA flowchart for the process of selecting and identifying studies.
Figure 2
Figure 2
Forest plot from the fixed and random-effects analysis: ABO Blood group susceptibility to venous thromboembolism in individuals with Factor V Leiden [34,35,36,37].
Figure 3
Figure 3
Publication bias of the ABO Blood group susceptibility to venous thromboembolism in individuals with Factor V Leiden [34,35,36,37].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Galanaud J.-P., Genty C., Sevestre M.-A., Brisot D., Lausecker M., Gillet J.-L., Rolland C., Righini M., Leftheriotis G., Bosson J.-L. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. Thromb. Haemost. 2011;105:31–39. - PubMed
    1. Smalberg J.H., Kruip M.J., Janssen H.L., Rijken D.C., Leebeek F.W., de Maat M.P. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: Similarities and differences. Arterioscler. Thromb. Vasc. Biol. 2011;31:485–493. doi: 10.1161/ATVBAHA.110.213371. - DOI - PubMed
    1. Rosendorff A., Dorfman D.M. Activated protein C resistance and factor V Leiden: A review. Arch. Pathol. Lab. Med. 2007;131:866–871. doi: 10.5858/2007-131-866-APCRAF. - DOI - PubMed
    1. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., van der Velden P.A., Reitsma P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67. doi: 10.1038/369064a0. - DOI - PubMed
    1. Mammen E.F. Current development in antithrombotic therapy. Semin. Thromb. Hemost. 2004;30:605–607. doi: 10.1055/s-2004-861501. - DOI - PubMed

LinkOut - more resources